U.S. FDA Accepts for Priority Review the Supplemental Biologics ... - Investing News Network

Vaccines

Pneumonia

Medical specialties

Medicine

Health

Pneumococcal conjugate vaccine

Pneumococcal vaccine

Pfizer

Pneumococcal polysaccharide vaccine

Pneumococcal infection

Streptococcus pneumoniae

Vaccine

Prevnar 13

Pfizer Inc.

United States

u.s. food and drug administration

U.S. FDA Accepts for Priority Review the Supplemental Biologics ... - Investing News Network. View article details on HISWAI: https://investingnews.com/u-s-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-pfizer-s-20-valent-pneumococcal-conjugate-vaccine-in-infants-and-children/